BioSpace News Archive

Systems Oncology, a biotechnology company, today announced that Dr. Spyro Mousses, CEO and Co-Founder of Systems Oncology, will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on Thursday, May 20 th at 12:40pm EST.

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced its support of the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research .

Halberd Corporation announces the commencement of its patented extra-corporeal process experimentation using lasers to eradicate disease.

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company overview at the Canaccord Genuity Virtual Musculoskeletal Conference. The conference is being conducted in a virtual format and the presentation will take place on Thursday, May 20, 2021, at 9:30 a.m. Eastern Time.

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Thomas Nusbickel to the newly created position of Chief Commercial Officer.

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today it plans to host a virtual information session on its pipeline product, HT-005 Z-Pods™ , a novel endocannibinoid treatment for patients with Cutaneous Lupus Erythematosus (CLE), on Tuesday, May 18th at 11:00am ET

Strongbridge Biopharma plc, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, announced that the U.S. Food and Drug Administration has accepted for review the Company’s New Drug Application for RECORLEV® for the treatment of endogenous Cushing’s syndrome.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (“CBN”), today reported financial results for the third quarter of fiscal year 2021 (“3Q21”) which ended March 31, 2021.

Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, announced the appointment of Christopher Rohde, Ph.D. to the Company’s Scientific Advisory Board, effective May 13, 2021.

- Apitegromab shows transformative potential in spinal muscular atrophy (SMA) with 74% of patients with non-ambulatory Type 2 and 3 SMA in the TOPAZ Phase 2 trial attaining a clinical improvement in HFMSE at 12 months - Mean increase from baseline in HFMSE of 6.2 points (across both evaluated doses) observed in younger non-ambulatory patients; up to 20-point increases in HFMSE observed with 35% of patients demonstrating a >10-point increase